Appendix 8: Data Extraction

Appendix 8 Table 1: Data Extraction Table (example based on Vaccine Preventive Disease)

Included Studies			Summary of Findings Table					
Author	Year	Comparison question	sample size (n)	Relative effect (95%CI)	Assumed Risk (control grp)	Correspondi ng risk (interventio n grp)	(n/N) intervention	(n/N) control
Zhang (202	14) Acellu	ar vaccines for preventing	whooping co	ugh in children	1	l		ı
		Acellular vs Whole- cell pertussis: Harms						
		Noncompletion due to adverse events: acellular versus whole cell pertussis	108909 (11 Studies)	RR: 0.23 (95%CI: 0.12-0.43)	n/a	n/a	n:248/ 80 060	n: 338/28 849
		2. Death (all causes)	122451 (16 Studies)	RR: 0.87 (95%CI: 0.62-1.22)	n/a	n/a	n: 81/86 863	n: 61/35 588
		3. Death (infection)	108909 (11 Studies)	RR: 0.97 (95%CI :0.23-4.16)	n/a	n/a	n: 5/22 154	n:3/12 344

Appendix 8, Table 2: Quality Assessment of Included Reviews using the AMSTAR Tool (example)

		SIGN 50/
		AMSTAR
Author	Title	Score
Zhang	Acellular vaccines for preventing whooping cough in children.	9 out of 11
2014		

April 17, 2017 - Protocol Systematic Review for Refugees and Migrants to EU/EEA

Appendix 8, Table 3: Quality of Evidence for Outcomes

	Quality of Evidence for Outcomes						
Included Studies							
Author	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Notes	
Zhang (2014) Acellular vaccines for preventing whooping cough in children							
Outcomes							
Noncompletion due to adverse events: acellular versus whole cell pertussis	Serious (1)	Not serious	Not Serious	Not Serious	Undetected	(1) Random sequence generation, allocation concealment is unclear Overall quality: Moderate (downgraded by 1)	

Appendix 8, Table 4. Selected outcomes

	Importance			
Tuberculosis				
Hepatotoxicity	Critical			
Active TB follow-up	Critical			
Drug-resistant TB	Critical			
Treatment limiting adverse events	Important			
Haematological adverse events	Important			
Hepatitis B				
Hepatocellular carcinoma	Critical			
HCC mortality	Critical			
HBeAg loss	Important			
HBV DNA loss	Important			
HBsAg loss	Important			
Histologic improvement	Important			
HBsAg carriage	Important			
Liver cancers (except non-hepatocellular carcinoma)	Important			
Hepatitis C				
Mortality due to HCV	Critical			
Hepatocellular Carcinoma	Critical			
Hospitalizations due to HCV	Important			
Quality of life	Important			
Sustained virological response rates (SVR), histological improvements due to treatment	Important			
Reduced HCV transmission	Important			
Harms of screening due to over diagnosis/overtreatment	Important			
Measles, mumps, rubella, polio and tetanus, diphtheria, pertussis, haemophilus influenzae type B				
Morbidity	Critical			
Mortality	Critical			
Vaccine efficacy	Important			
Non-completion due to adverse events	Important			

Intestinal parasites

Overall cure	Critical
Mortality due to schistosomiasis	Critical
Risk of severe strongyloidiasis in immunosuppressed patients	Important
% egg reduction	Important
Micro haematuria	Important
Haemoglobin	Important